Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-MUC1 CAR T and PD-1 Knockout T Cells in Advanced NSCLC
NCT03525782Phase 2
Key facts
- Status
- Unknown
- Start
- Feb 2018
- Primary completion
- Jan 2021
- Countries
- 1
- Sponsor
- The First Affiliated Hospital of Guangdong Pharmaceutical University
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Drugs
- anti-muc1 car-t cellspd-1 knockout t cells
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, randomised, open-label trial of anti-muc1 car-t cells and pd-1 knockout t cells in non-small cell lung cancer (NSCLC), sponsored by The First Affiliated Hospital of Guangdong Pharmaceutical University. Status: unknown.
02
Design
- Study design
- RandomizedOpen-label
03
Registry description
The study is to assess the safety and efficacy of the anti-MUC1 CAR T cells and /or PD-1 knockout engineered T cells for patients with advanced non-small cell lung cancer.
Beyond the preview
Go deeper on NCT03525782.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03525782.